Oncaspar

pegaspargase · Les Laboratoires Servier
AUTHORISED IN THE EU

What Oncaspar is used for

Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Oncaspar
Active substance
pegaspargase
Disease area
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Medicine group
Antineoplastic agents
ATC code
L01XX24
Marketing authorisation holder
Les Laboratoires Servier
Authorised in the EU since
2016

Official information

In the USA

Same active substance: Oncaspar

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Oncaspar used for?

Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

What is the active substance in Oncaspar?

Oncaspar contains pegaspargase.

Who makes Oncaspar?

The EU marketing authorisation holder is Les Laboratoires Servier.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.